<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847326</url>
  </required_header>
  <id_info>
    <org_study_id>12-1554</org_study_id>
    <secondary_id>NCI-2012-02179</secondary_id>
    <nct_id>NCT01847326</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer</brief_title>
  <official_title>Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation when given together with carboplatin followed by chemoradiation in&#xD;
      treating patients with recurrent head and neck cancer. Drugs used in chemotherapy, such as&#xD;
      paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, fluorouracil, and&#xD;
      hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill&#xD;
      tumor cells. Giving paclitaxel albumin-stabilized nanoparticle formulation followed by&#xD;
      chemoradiation therapy may be an effective treatment for head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of&#xD;
      nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) when given in&#xD;
      combination with FHX (5 fluorouracil [fluorouracil], hydroxyurea and twice daily radiation,&#xD;
      in good induction responders) and of nab-paclitaxel added to hypofractionated radiotherapy&#xD;
      for poor responders.&#xD;
&#xD;
      II. To explore the feasibility of a more rapid palliative chemoradiotherapy approach&#xD;
      inpatients with refractory disease as demonstrated by failure to respond to initial&#xD;
      chemotherapy.&#xD;
&#xD;
      III. To explore the role of induction chemotherapy as a predictive tool for definitive head&#xD;
      and neck cancer management of previously treated patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Progression-free survival (PFS) (time to disease progression or death from any cause) on&#xD;
      both study arms.&#xD;
&#xD;
      II. Overall survival and response rates in both arms.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the correlation of secreted protein, acidic, cysteine-rich (SPARC) expression&#xD;
      in head and neck cancer and response to therapy.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation.&#xD;
&#xD;
      RE-INDUCTION THERAPY (WEEKS 1-6): Patients receive paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation intravenously (IV) over 30 minutes on days 1 and 8 and carboplatin IV over 30&#xD;
      minutes on day 1. Courses repeat every 21 days for 2 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients achieving good response undergo surgical&#xD;
      resection and proceed to chemoradiation within 4-6 weeks.&#xD;
&#xD;
      AFHX REGIMEN: Patients achieving response to re-induction therapy receive hydroxyurea orally&#xD;
      (PO) every 12 hours for 6 days (11 doses) beginning on day 0, fluorouracil IV continuously&#xD;
      over 120 hours beginning on day 0, and paclitaxel albumin-stabilized nanoparticle formulation&#xD;
      IV over 30 minutes on day 1. Patients also undergo radiation therapy twice daily (BID) on&#xD;
      days 1-5. Courses repeat every 14 days for 5 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PACLITAXEL + RADIATION (AXX) REGIMEN: Patients not achieving response to re-induction therapy&#xD;
      receive paclitaxel albumin-stabilized nanoparticle formulation IV and undergo&#xD;
      hypofractionated radiation therapy on day 1. Courses repeat every 7 days for 5 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up monthly for 3 months, every 3&#xD;
      months for 2 years, every 6 months for 2 years, and then yearly thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose of paclitaxel albumin-stabilized nanoparticle formulation in combination with fluorouracil, hydroxyurea, and radiation therapy, determined according to incidence of DLT graded using the National Cancer Institute (NCI) CTCAE 4.0</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose of paclitaxel albumin-stabilized nanoparticle formulation in combination with radiation therapy, determined according to incidence of DLT graded using the NCI CTCAE 4.0</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>The time from the date of registration to the date of progressive disease or death, assessed up to 1 year</time_frame>
    <description>Statistical significance will be determined by a two-sided P value =&lt; 0.05. Progression-free survival curves will be calculated using the Kaplan-Meier method, and median progression-free survival time, along with 90% confidence intervals will be derived using the procedure described in Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time from the date of registration to the date of death, assessed up to 1 year</time_frame>
    <description>Statistical significance will be determined by a two-sided P value =&lt; 0.05. Overall survival curves will be calculated using the Kaplan-Meier method, and median overall survival time, along with 90% confidence intervals will be derived using the procedure described in Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (complete response [CR] + partial response [PR])</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The objective response rate (CR + PR) and associated 90% confidence interval will be determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Verrucous Carcinoma of the Larynx</condition>
  <condition>Recurrent Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Salivary Gland Squamous Cell Carcinoma</condition>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
    <other_name>ABI-007</other_name>
    <other_name>nab paclitaxel</other_name>
    <other_name>nab-paclitaxel</other_name>
    <other_name>nanoparticle albumin-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
    <other_name>HU</other_name>
    <other_name>HYD</other_name>
    <other_name>Hydrea</other_name>
    <other_name>Hydroxycarbamide</other_name>
    <other_name>Hydurea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hyperfractionated radiation therapy</intervention_name>
    <description>Undergo hyperfractionated radiation therapy</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (induction therapy and AFHX or AXX)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological documentation of recurrent head and neck cancer requiring&#xD;
             regional therapy&#xD;
&#xD;
          -  Recurrent or second primary, previously irradiated squamous cell carcinoma of the head&#xD;
             and neck (SCCHN) without clinically measurably metastatic disease&#xD;
&#xD;
          -  Prior radiation therapy completed &gt;= 4 months, and/or chemotherapy completed &gt;= 1&#xD;
             month before study entry, and patient should have recovered from any adverse effects&#xD;
&#xD;
          -  Predominance of disease that is amenable to radiotherapy&#xD;
&#xD;
          -  Measurable disease prior to induction chemotherapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of one or less&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males must use an effective&#xD;
             contraception method during treatment and for three months after completing treatment&#xD;
&#xD;
          -  Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at&#xD;
             screening for patients of childbearing potential&#xD;
&#xD;
          -  Patients must have &lt; grade 2 pre-existing peripheral neuropathy (per Common&#xD;
             Terminology Criteria for Adverse Events [CTCAE])&#xD;
&#xD;
          -  Leukocyte &gt;= 3,000/ul&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/ul&#xD;
&#xD;
          -  Platelets &gt;= 1000,000/ul&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             &lt; 2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance (CrCl) &gt; 45 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously untreated patients with locoregional-only disease are not eligible&#xD;
&#xD;
          -  Patients who have had chemotherapy within 4 weeks prior to entering the study, or&#xD;
             those who have not recovered from adverse events due to agents administered more than&#xD;
             4 weeks earlier&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical composition&#xD;
             agents used in the study&#xD;
&#xD;
          -  Patients with pre-existing grade 2 or greater peripheral neuropathy, defined as&#xD;
             sensory alteration or paresthesia (including tingling), interfering with function&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas de Souza</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

